![Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan | SpringerLink Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40121-021-00576-7/MediaObjects/40121_2021_576_Fig2_HTML.png)
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan | SpringerLink
![SOF/VEL/VOX safe, effective for rescue hepatitis C treatment | Latest news for Doctors, Nurses and Pharmacists | Pharmacy SOF/VEL/VOX safe, effective for rescue hepatitis C treatment | Latest news for Doctors, Nurses and Pharmacists | Pharmacy](https://pubmiddleware.mims.com/resource/image/B8440EF6-3C40-493B-A9B9-A874010808FC/OriginalThumbnail/THUMBNAIL_Fotolia_151243919_Subscription_Monthly_M.jpg)
SOF/VEL/VOX safe, effective for rescue hepatitis C treatment | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
![SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis. - ppt download SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis. - ppt download](https://slideplayer.com/9898637/32/images/slide_1.jpg)
SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis. - ppt download
![Sait 99634 SAITAC-PAD-VEL SOF - Platos de apoyo para discos con velcro (150 mm, 150 mm de diámetro, 15 Fori, 3 unidades) : Amazon.es: Industria, empresas y ciencia Sait 99634 SAITAC-PAD-VEL SOF - Platos de apoyo para discos con velcro (150 mm, 150 mm de diámetro, 15 Fori, 3 unidades) : Amazon.es: Industria, empresas y ciencia](https://m.media-amazon.com/images/W/IMAGERENDERING_521856-T1/images/I/61-JesoN3bL._SX342_.jpg)
Sait 99634 SAITAC-PAD-VEL SOF - Platos de apoyo para discos con velcro (150 mm, 150 mm de diámetro, 15 Fori, 3 unidades) : Amazon.es: Industria, empresas y ciencia
![Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis](https://f6publishing.blob.core.windows.net/de2c21e5-7204-4e91-983b-18b4a602349a/WJH-14-1248-g002.png)
Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
![Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Prior Treartment Failures with Glecaprevir/Pibrentasvir (G/P) in Chronic Hepatitis C Infection Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Prior Treartment Failures with Glecaprevir/Pibrentasvir (G/P) in Chronic Hepatitis C Infection](https://www.natap.org/2018/images%20/111618/111618-12/1116181.gif)
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Prior Treartment Failures with Glecaprevir/Pibrentasvir (G/P) in Chronic Hepatitis C Infection
![A Case Series of Safety and Efficacy of Crushed Sofosbuvir/Velpatasvir in Hepatitis C Infected Patients A Case Series of Safety and Efficacy of Crushed Sofosbuvir/Velpatasvir in Hepatitis C Infected Patients](https://www.natap.org/2021/images/111221/111221-14/1112211.gif)
A Case Series of Safety and Efficacy of Crushed Sofosbuvir/Velpatasvir in Hepatitis C Infected Patients
![Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan | Scientific Reports Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-93095-x/MediaObjects/41598_2021_93095_Fig1_HTML.png)
Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan | Scientific Reports
![HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection](http://www.hcv-trials.com/studies/POLARIS-1/big/Diapositive1.jpg)
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
![Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis](https://f6publishing.blob.core.windows.net/de2c21e5-7204-4e91-983b-18b4a602349a/WJH-14-1248-g001.png)
Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
![HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection](http://www.hcv-trials.com/studies/POLARIS-2/Diapositive1.jpg)
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
![SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study](https://www.natap.org/2017/images/102317/102317-11/1023171.gif)
SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study
![gTt-VIH | Gilead solicita a la FDA la autorización de sofosbuvir/velpatasvir, un comprimido con actividad pangenotípica frente al VHC gTt-VIH | Gilead solicita a la FDA la autorización de sofosbuvir/velpatasvir, un comprimido con actividad pangenotípica frente al VHC](http://gtt-vih.org/files/images/imagenes/LA%20NOTICIA%20DEL%20DIA/2015_10/LND_2015_11_02_A.jpg)
gTt-VIH | Gilead solicita a la FDA la autorización de sofosbuvir/velpatasvir, un comprimido con actividad pangenotípica frente al VHC
![Treatment With SOF/VEL or SOF/VEL/VOX Is Well Tolerated and Results in High SVR12 in Genotype 1-6 HCV-Infected Patients With Minimal Fibrosis: a Retrospective Analysis of the ASTRAL and POLARIS Clinical Studies Treatment With SOF/VEL or SOF/VEL/VOX Is Well Tolerated and Results in High SVR12 in Genotype 1-6 HCV-Infected Patients With Minimal Fibrosis: a Retrospective Analysis of the ASTRAL and POLARIS Clinical Studies](https://www.natap.org/2017/images/042117/042117-1/0421171.gif)
Treatment With SOF/VEL or SOF/VEL/VOX Is Well Tolerated and Results in High SVR12 in Genotype 1-6 HCV-Infected Patients With Minimal Fibrosis: a Retrospective Analysis of the ASTRAL and POLARIS Clinical Studies
![HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection](http://www.hcv-trials.com/studies/ASTRAL-3/big/Diapositive4.jpg)